334 related articles for article (PubMed ID: 17307426)
1. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.
Stocker DJ; Taylor AJ; Langley RW; Jezior MR; Vigersky RA
Am Heart J; 2007 Mar; 153(3):445.e1-6. PubMed ID: 17307426
[TBL] [Abstract][Full Text] [Related]
2. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.
Hedblad B; Zambanini A; Nilsson P; Janzon L; Berglund G
J Intern Med; 2007 Mar; 261(3):293-305. PubMed ID: 17305652
[TBL] [Abstract][Full Text] [Related]
3. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
Kadoglou NP; Tsanikidis H; Kapelouzou A; Vrabas I; Vitta I; Karayannacos PE; Liapis CD; Sailer N
Metabolism; 2010 Mar; 59(3):373-9. PubMed ID: 19815243
[TBL] [Abstract][Full Text] [Related]
4. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.
Davidson M; Meyer PM; Haffner S; Feinstein S; D'Agostino R; Kondos GT; Perez A; Chen Z; Mazzone T
Circulation; 2008 Apr; 117(16):2123-30. PubMed ID: 18413496
[TBL] [Abstract][Full Text] [Related]
5. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
[TBL] [Abstract][Full Text] [Related]
6. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study.
Langenfeld MR; Forst T; Hohberg C; Kann P; Lübben G; Konrad T; Füllert SD; Sachara C; Pfützner A
Circulation; 2005 May; 111(19):2525-31. PubMed ID: 15883215
[TBL] [Abstract][Full Text] [Related]
7. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis.
Vanderpoel DR; Hussein MA; Watson-Heidari T; Perry A
Clin Ther; 2004 Dec; 26(12):2066-75. PubMed ID: 15823770
[TBL] [Abstract][Full Text] [Related]
8. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
[TBL] [Abstract][Full Text] [Related]
9. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial.
Schaumberg DA; Glynn RJ; Jenkins AJ; Lyons TJ; Rifai N; Manson JE; Ridker PM; Nathan DM
Circulation; 2005 May; 111(19):2446-53. PubMed ID: 15867184
[TBL] [Abstract][Full Text] [Related]
10. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus.
Kadoglou NP; Iliadis F; Angelopoulou N; Perrea D; Liapis CD; Alevizos M
Diabet Med; 2008 Mar; 25(3):333-40. PubMed ID: 18307460
[TBL] [Abstract][Full Text] [Related]
13. Effect of short term intensive multitherapy on carotid intima-media thickness in patients with newly diagnosed type 2 diabetes mellitus.
Guo LX; Pan Q; Wang XX; Li H; Zhang LN; Chi JM; Wang Y
Chin Med J (Engl); 2008 Apr; 121(8):687-90. PubMed ID: 18701019
[TBL] [Abstract][Full Text] [Related]
14. The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study.
Sarafidis PA; Lasaridis AN; Nilsson PM; Mouslech TF; Hitoglou-Makedou AD; Stafylas PC; Kazakos KA; Yovos JG; Tourkantonis AA
Metabolism; 2005 Sep; 54(9):1236-42. PubMed ID: 16125536
[TBL] [Abstract][Full Text] [Related]
15. Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial.
Meisner F; Walcher D; Gizard F; Kapfer X; Huber R; Noak A; Sunder-Plassmann L; Bach H; Haug C; Bachem M; Stojakovic T; März W; Hombach V; Koenig W; Staels B; Marx N
Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):845-50. PubMed ID: 16410460
[TBL] [Abstract][Full Text] [Related]
16. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients.
Kiyici S; Ersoy C; Kaderli A; Fazlioglu M; Budak F; Duran C; Gul OO; Sigirli D; Baran I; Tuncel E; Erturk E; Imamoglu S
Diabetes Res Clin Pract; 2009 Oct; 86(1):44-50. PubMed ID: 19674806
[TBL] [Abstract][Full Text] [Related]
17. Fruit consumption is associated with lower carotid intima-media thickness and C-reactive protein levels in patients with type 2 diabetes mellitus.
Zhu Y; Zhang Y; Ling W; Feng D; Wei X; Yang C; Ma J
J Am Diet Assoc; 2011 Oct; 111(10):1536-42. PubMed ID: 21963020
[TBL] [Abstract][Full Text] [Related]
18. Independent anti-inflammatory effect of insulin in newly diagnosed type 2 diabetes.
Mao XM; Liu H; Tao XJ; Yin GP; Li Q; Wang SK
Diabetes Metab Res Rev; 2009 Jul; 25(5):435-41. PubMed ID: 19405039
[TBL] [Abstract][Full Text] [Related]
19. Vertebral fractures in males with type 2 diabetes treated with rosiglitazone.
Mancini T; Mazziotti G; Doga M; Carpinteri R; Simetovic N; Vescovi PP; Giustina A
Bone; 2009 Oct; 45(4):784-8. PubMed ID: 19527806
[TBL] [Abstract][Full Text] [Related]
20. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
Krentz A
Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
